Showing results (291-300 of 334) with videos related to
Sort By:
Pageof 34
Journal of Gynecology Obstetrics and Human Reproduction|March 16, 2024
Maternal and neonatal outcomes of French prospective multicenter cohort study COVIPREG during the first two COVID-19 wavesAlexandre J Vivanti, Camille Couffignal, Jeanne Sibiude, et al.Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|October 19, 2017
Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 seasonMarc Rondy, Alin Gherasim, Itziar Casado, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 16, 2014
Prevention of infections during primary immunodeficiencyClaire Aguilar, Marion Malphettes, Jean Donadieu, et al.Journal of Crohn'S & Colitis|September 10, 2015
Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective StudyOdile Launay, Vered Abitbol, Anne Krivine, et al.Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 3, 2022
Prevalence of post-acute coronavirus disease 2019 symptoms twelve months after hospitalization in participants retained in follow-up: analyses stratified by gender from a large prospective cohortJade Ghosn, Delphine Bachelet, Marine Livrozet, et al.Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 17, 2022
One-month humoral response following two or three doses of messenger RNA coronavirus disease 2019 vaccines as primary vaccination in specific populations in France: first results from the Agence Nationale Recherche contre le Sida (ANRS)0001S COV-POPART cohortPaul Loubet, Linda Wittkop, Laetitia Ninove, et al.Plos Pathogens|June 27, 2020
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II TrialYves Lévy, Christine Lacabaratz, Kim Ellefsen-Lavoie, et al.International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|June 2, 2024
Humoral response after mRNA COVID-19 primary vaccination and single booster dose in people living with HIV compared to controls: A French nationwide multicenter cohort study-ANRS0001s COV-POPARTPaul Loubet, Jean-Daniel Lelievre, Alexis François, et al.Clinical Drug Investigation|January 16, 2026
Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-studyAndrew Ustianowski, Myron J Levin, Stephane De Wit, et al.The Lancet. Rheumatology|August 1, 2025
Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trialJacques Morel, Emmanuelle Dernis, Christian Roux, et al.Pageof 34